Article
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Annals of neurology - 1 Aug 2009
Piepers Sanne, Veldink Jan H, de Jong Sonja W, van der Tweel Ingeborg, van der Pol W-Ludo, Uijtendaal Esther V, Schelhaas H Jurgen, Scheffer Hans, de Visser Marianne, de Jong J M B Vianney, Wokke John H J, Groeneveld Geert Jan, van den Berg Leonard H
Abstract excerpt
OBJECTIVE: To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed antioxidative and antiapoptotic properties and reduced glutamate toxicity in preclinical studies, is safe and effective in amyotrophic lateral sclerosis (ALS) using a sequential trial design. METHODS: Between April 2005 and January 2007, 163 ALS patients received VPA 1,500mg or placebo daily. Primary end point was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.